Observed-to-expected Ratio for Adherence to Treatment Guidelines As a Quality of Care Indicator for Ovarian Cancer
Overview
Affiliations
Objective: To develop an observed-to-expected ratio (O/E) for adherence to National Comprehensive Cancer Network (NCCN) ovarian cancer treatment guidelines as a risk-adjusted hospital measure of quality care correlated with disease-specific survival.
Methods: Consecutive patients with stages I-IV epithelial ovarian cancer were identified from the California Cancer Registry (1/1/96-12/31/06). Using a fit logistic regression model, O/E for guideline adherence was calculated for each hospital and distributed into quartiles stratified by hospital annual case volume: lowest O/E quartile or annual hospital case volume <5, middle two O/E quartiles and volume ≥5, and highest O/E quartile and volume ≥5. A multivariable logistic regression model was used to characterize the independent effect of hospital O/E on ovarian cancer-specific survival.
Results: Overall, 18,491 patients were treated at 405 hospitals; 37.3% received guideline adherent care. Lowest O/E hospitals (n=285) treated 4661 patients (25.2%), mean O/E=0.77±0.55 and median survival 38.9months (95%CI=36.2-42.0months). Intermediate O/E hospitals (n=85) treated 8715 patients (47.1%), mean O/E=0.87±0.17 and median survival of 50.5months (95% CI=48.4-52.8months). Highest O/E hospitals (n=35) treated 5115 patients (27.7%), mean O/E=1.34±0.14 and median survival of 53.8months (95% CI=50.2-58.2months). After controlling for other variables, treatment at highest O/E hospitals was associated with independent and statistically significant improvement in ovarian cancer-specific survival compared to intermediate O/E (HR=1.06, 95% CI=1.01-1.11) and lowest O/E (1.16, 95% CI=1.10-1.23) hospitals.
Conclusions: Calculation of hospital-specific O/E for NCCN treatment guideline adherence, combined with minimum case volume criterion, as a measure of ovarian cancer quality of care is feasible and is an independent predictor of survival.
Noy M, Rich B, Llorente R, Kwon D, Abramowitz M, Mahal B Adv Radiat Oncol. 2021; 7(1):100832.
PMID: 34869943 PMC: 8626664. DOI: 10.1016/j.adro.2021.100832.
Management of advanced ovarian cancer in Spain: an expert Delphi consensus.
Redondo A, Oaknin A, Rubio M, Barretina-Ginesta M, de Juan A, Manso L J Ovarian Res. 2021; 14(1):72.
PMID: 34039386 PMC: 8157411. DOI: 10.1186/s13048-021-00816-x.
Hawarden A, Russell B, Gee M, Kayali F, Clamp A, Crosbie E BMC Cancer. 2021; 21(1):378.
PMID: 33832445 PMC: 8034099. DOI: 10.1186/s12885-021-08019-9.
Villanueva C, Chang J, Ziogas A, Bristow R, Vieira V Cancer Epidemiol. 2020; 69:101825.
PMID: 33022472 PMC: 7710533. DOI: 10.1016/j.canep.2020.101825.
Mathews K, Goel N, Vargas-Torres C, Olson A, Zhou J, Powell C Lung. 2020; 198(4):637-644.
PMID: 32495192 PMC: 7791596. DOI: 10.1007/s00408-020-00364-z.